Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2022
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Avelumab for treating metastatic Merkel cell carcinoma (TA517)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 April 2021Published: 11 April 2018
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 April 2021
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 March 2021
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2019
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2019
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 October 2018
Vismodegib for treating basal cell carcinoma (TA489)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 November 2017
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published: 25 November 2015
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published: 7 October 2015
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2017
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2016
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 February 2016
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2015Published: 12 December 2012
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2014
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2014
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2012
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 April 2021
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over [ID6189]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy ID6414Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC